# Guangzhou Sianxin Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/guangzhou-sianxin-biotechnology-co

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Website: www.cyanvaccine.com
- Total disclosed funding: $47M
- Latest round: Series A (Jan 26, 2022)
- Investors on record: 2

## About

Established in 2019 and based in Guangzhou, China, Guangzhou Sianxin Biotechnology Co., Ltd. is a medical health company that focuses on research and development of innovative vaccine vector technologies and the development of novel vaccines. The company has completed 4 rounds of funding as of 2022. The company's founder, Dr. Biao He, is a tenured and Fred Davison Professor at the University of Georgia. In August 2021, this company completed a GMP-compliant viral vaccine development and pilot production site. In June 2021, the company received clinical trial approval from the US FDA for the development of a new coronavirus vaccine and initiated Phase I clinical trials in August.

The company self-developed products include PIV5 virus vector platform and bioreactor serum-free continuous perfusion culture technology platform for virus vaccine preparation. PIV5 virus vector platform has vaccines for viruses such as COVID-19, influenza virus, respiratory syncytial virus, middle east respiratory syndrome virus and mycobacterium tuberculosis. The bioreactor serum-free continuous perfusion culture technology platform for virus vaccine preparation has cell scale up and freeze storage technology, large scale cell seed preparation technology, bioreactor continuous perfusion serum-free large scale culture Vero cell technology, virus vaccine purification technology, virus vaccine heat stabilised formulation and lyophilised formulation technology.

## Funding rounds

- Series A, Jan 26, 2022, $47M — Sunz Fund, Zhongda Venture Capital

## Investors

- Sunz Fund (https://capitalatlas.ai/funds/sunz-fund) — Series A
- Zhongda Venture Capital (https://capitalatlas.ai/funds/zhongda-venture-capital) — Series A